FDA Approves Inflectra (infliximab-dyyb) a Biosimilar to Remicade

April 5, 2016 -- The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. Inflectra is...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news